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Background: A variety of instruments are used to measure health related quality of life. Few data exist on the
performance and agreement of different instruments in a depressed population. The aim of this study was to
investigate agreement between, and suitability of, the EQ-5D-3L, EQ-5D Visual Analogue Scale (EQ-5D VAS), SF-6D
and SF-12 new algorithm for measuring health utility in depressed patients.
Methods: The intraclass correlation coefficient (ICC) and Bland and Altman approaches were used to assess
agreement. Instrument sensitivity was analysed by: (1) plotting utility scores for the instruments against one
another; (2) correlating utility scores and depressive symptoms (Beck Depression Inventory (BDI)); and (3) using
Tukey’s procedure. Receiver Operating Characteristic (ROC) analysis assessed instrument responsiveness to change.
Acceptability was assessed by comparing instrument completion rates.
Results: The overall ICC was 0.57. Bland and Altman plots showed wide limits of agreement for each pair wise
comparison, except between the SF-6D and SF-12 new algorithm. Plots of utility scores displayed ’ceiling effects’ in
the EQ-5D-3L index and ’floor effects’ in the SF-6D and SF-12 new algorithm. All instruments showed a negative
monotonic relationship with BDI, but the EQ-5D-3L index and EQ-5D VAS could not differentiate between
depression severity sub-groups. The SF-based instruments were better able to detect changes in health state over
time. There was no difference in completion rates of the four instruments.
Conclusions: There was a lack of agreement between utility scores generated by the different instruments.
According to the criteria of sensitivity, responsiveness and acceptability that we applied, the SF-6D and SF-12 may
be more suitable for the measurement of health related utility in a depressed population than the EQ-5D-3L, which
is the instrument currently recommended by NICE.
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The National Institute for Health and Care Excellence
(NICE) guidance on the management of depression identi-
fies several priorities including accurate case recognition,
optimal use of medication and effective delivery of psycho-
logical therapies [1]. This guidance highlights the need to
identify cost-effective interventions and the use of cost per
quality adjusted life years (QALYs) for this purpose. Meas-
uring health related quality of life (HRQoL) to construct
QALYs can be conducted in a number of ways, including* Correspondence: Nicholas.Turner@bristol.ac.uk
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reproduction in any medium, provided the orusing various ‘off the shelf ’ instruments to define and value
an individual’s health state (known as health utility) [2].
However, if the scores produced by different instruments
differ markedly, this will impact on estimates of cost-
effectiveness that are obtained and may lead to discrepant
or uncertain conclusions as to whether or not an interven-
tion should be recommended/funded.
NICE currently recommends using the EQ-5D-3L ques-
tionnaire to measure HRQoL, though this instrument has
been widely criticised for a number of reasons for example,
being insensitive in certain conditions such as depression
[3,4] and for ignoring considerable individual variation in
the ordering of health states [5]. Research comparing
methods of calculating HRQoL has previously shown that
different instruments do not provide comparable estimatesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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levels of agreement between the SF-6D, Health Utilities
Index 2, Health Utilities Index 3 and a Feelings Therm-
ometer within a Diabetic population [6]. This lack of
comparability has led some observers to suggest that in
certain conditions one instrument may be recommended
above others. For example, the Health Utilties Index 3
has recently been recommended as the most suitable in-
strument for measuring QALYs in studies of retinopathy
[7]. The accurate measurement of HRQoL in depressed
patients is particularly important given the impact this
condition has on physical, emotional and social aspects
of an individual’s overall well-being [8]. However, the in-
vestigation of health utility in patients with depression
has been very limited, despite depression being a leading
cause of disability worldwide [9]. The vast majority of
previous comparison studies have not included samples
from this population, have focused on common mental
health disorders grouped together (not just depression)
or used a very small sample size, presented mainly sum-
mary statistics or only assessed one aspect of instrument
suitability [10-12]. As such the comparability of values
of HRQoL produced by different instruments in patients
with depression is unclear. The evidence from other dis-
ease areas suggests that the instruments are unlikely to
provide comparable scores. It is therefore important to
investigate this and, if true, to determine whether one
instrument may be more suitable than others. Further-
more, the development of a relatively new approach to
calculating health utility based on use of the SF-12 ques-
tionnaire highlights the need to understand the differ-
ences between the various instruments used to calculate
health utility [13].
The aim of the current study was to investigate the
extent of agreement between, and the suitability of, dif-
ferent instruments for measuring health utility in de-
pressed patients. Data from the Cognitive behavioural
therapy as an adjunct to pharmacotherapy for treatment
resistant depression in primary care (CoBalT) trial [14]
were used to compare the health utility values obtained
from four different instruments: (1) EQ-5D-3L [15,16];
(2) EQ-5D Visual Analogue Scale (EQ-5D VAS) [17];
(3), SF-6D [18]; and (4) SF-12 new algorithm [13], for
primary care based patients with treatment resistant de-
pression. The aspects investigated were: the level of
agreement between the health utility values generated
by the instruments; instrument sensitivity (ceiling/floor
effects and discriminatory ability); responsiveness of the
instruments to changes in depressed state; and the ac-
ceptability of the instruments in terms of completion
rates. We assessed whether the four approaches to meas-
uring health utility in depressed patients could be used
interchangeably, and if not, which method performed
best in this setting.Methods
Participants
This was a secondary analysis of data collected as part of
the CoBalT study, a randomised controlled trial examin-
ing the effectiveness of cognitive behavioural therapy as
an adjunct to usual care that included pharmacotherapy
for patients with treatment resistant depression in pri-
mary care. Individuals were eligible for the trial if they
were aged between 18–75 years, were currently taking
antidepressant medication and had been doing so at an
adequate dose for at least 6 weeks, scored 14 or more on
the Beck Depression Inventory (BDI) (second version)
[19] and met the ICD-10 criteria for depression (assessed
using the Clinical Interview Schedule – Revised form
[20]). Participants were followed up at intervals of three
months for a year with health utility information being
collected at baseline, six and twelve months [14].
Health utility measures
Health utility data were collected from self-completed
questionnaires that participants completed in the pres-
ence of a research assistant who could provide clarifica-
tion about what a question was asking, if required.
EQ-5D-3L
The EQ-5D-3L provides a simple, generic, single index
value reflecting HRQoL. It comprises five self-report items
that ask about five health domains with respect to “today”
with three possible response categories: 1) no problems;
2) some problems; and 3) severe problems. The EQ-5D-3L
is therefore able to represent 243 (35) distinct health states
[15]. These states may then be converted into a single
index value by applying published reference weights (for
CoBalT, the UK population valuation set [16]) to each do-
main response and subtracting the total of these weights
from one [2].
EQ-5D visual analogue scale
The EQ-5D VAS also seeks to assign individuals a single
index value representing health status. Respondents are
asked to record how good or bad their health is on a verti-
cal thermometer-like line with a scale ranging from zero
(representing worst imaginable state) to 100 (best imagin-
able state). The reported figure may then be rescaled by
dividing by 100 to scale between zero and one [17].
SF-6D
The SF-6D algorithm provides a way of estimating a
preference-based single index measure from a generic
quality of life questionnaire (the Short-Form 36 (SF-36))
[18], that is a common outcome in many health research
studies including randomised trials. Health states can be
derived from the six multi-level health dimensions of the
SF-36 questionnaire. In total, 18,000 different health states
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mensions have five levels and one dimension has four
levels (62 × 53 × 41 = 18,000). Preference weights for each
dimension allow the prediction of health utility values for
all possible health states [18]. The briefer 12-item (SF-12
revised acute version) quality of life questionnaire [21] was
used in the CoBalT study. At the time the CoBalT study
began, no algorithm was available to permit the calculation
of health utility values from the SF-12. Therefore, an add-
itional four questions from the SF-36 were included, in line
with established procedures [2], to allow the SF-6D algo-
rithm to be applied to derive health utility scores for each
individual.
SF-12 New algorithm instrument
The SF-12 questionnaire is commonly used as a HRQoL
outcome measure. It contains 12 items that map onto 12
of the 36 items from the SF-36 questionnaire. Brazier &
Roberts’ have recently published an algorithm [13] that
permits estimation of a preference based measure from
the SF-12 questionnaire (without the need for additional
questions as detailed for the SF-6D algorithm).
Depression measure
Depression was measured using the BDI, which is a self-
report inventory consisting of 21 multiple choice questions
about the respondent’s feelings in the past two weeks. Each
question has four potential response options that score
from 0–3. The scores for each question can be summed to
produce a total score ranging from 0 to 63. This total score
can then be categorised according to severity: (1) not de-
pressed (BDI score <14); (2) mild depression (BDI score
14–19); (3) moderate depression (BDI score 20–28) and
(4) severe depression (BDI score ≥29) [19].
Statistical analysis
All analyses were carried out using Stata (version 12.1).
The assessments of agreement, sensitivity and accept-
ability were carried out using the 12 month follow up
data. Analysis of responsiveness to change was carried
out comparing the 12 month data with baseline (as this
was that comparison made in the economic evaluation
of the CoBalT trial).
Agreement
To avoid differences in estimates of cost-effectiveness
arising from the use of varying instruments, the four in-
struments should generate health utility scores that have
a high level of agreement. The intraclass correlation co-
efficient (ICC) was calculated to assess the overall agree-
ment between the four different methods for calculating
health utility. Pairwise agreements between the different
instrument scores (such as EQ-5D-3L index vs. SF-6D,
EQ-5D-3L index vs. SF-12 new algorithm) was assessedusing the Bland and Altman approach [22]. For each pair-
wise analysis the difference between the two measures was
plotted against the mean measurement for those two in-
struments for each individual, along with the limits of
agreement (the range of values that would be expected to
include 95% of individual differences).
Sensitivity
A good instrument should be able to produce scores for
various degrees of ill and good health with an adequate
degree of accuracy, effectively detecting and representing
differences between individuals. Previous studies have
reported that certain instruments may lack sensitivity at
the tails of the utility index [23,24]. Potential ‘ceiling’
and ‘floor’ effects were examined by plotting the health
utility scores generated by each of the different instru-
ments against one another.
To be a useful and valid measure of health utility in de-
pressed patients the health utility scores generated by the
instruments should decrease monotonically with worsen-
ing depression score and should differ markedly between
groups based on severity of depression [25]. These hypoth-
eses were investigated by calculating the Spearman’s rank
correlation coefficients between the health utility scores
and BDI scores, and by carrying out the Tukey-Kramer
multiple comparison procedure testing for differences be-
tween groups based on severity of depression [26,27].
Responsiveness to change
An instrument measuring health utility should be able
to detect and represent a change in an individual’s health
over time. A binary variable was created dichotomising
participants into those with at least a 50% reduction in
BDI score at 12 months compared to baseline and those
who did not (the primary outcome in the CoBalT trial),
and a variable representing the change in health utility
score in this time period was also generated. Receiver
Operating Characteristic (ROC) curves (a plot of sensi-
tivity versus 1-specificity) for the instruments were then
plotted. The area under an ROC curve (AUC) is a meas-
ure of the discriminatory ability of an instrument as it
represents how accurately the change in health utility
score reflects whether or not an individual is classified
as improved or not [28,29]. The equality of the AUCs
produced for the instruments was then tested using the
method of De Long et al. [30].
Acceptability
Acceptability was assessed with respect to the comple-
tion rates of the four instruments [31,32]. The propor-
tion of respondents who provided enough information
for the calculation of a health utility score for each of
the different instruments was calculated and compared
by means of the Marascuilo Procedure [33,34]. If the
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than the calculated critical value this suggests that there
is evidence of a difference between the completion rates.
Results
Of the 469 individuals who were randomised within the
CoBalT study, 396 were followed up at 12 months. A
health utility score could be calculated for 395 participants
using the EQ-5D-3L, for 394 using the EQ-5D VAS and
for 393 using the SF-6D and the SF-12 new algorithm. A
total of 393 participants had completed all four instru-
ments. The mean scores for the four instruments are simi-
lar; however, there was greater variance associated with the
EQ-5D based measures (Table 1).
Agreement
The overall ICC was 0.57, suggesting a fairly low
level of agreement between the four instruments. This
was reinforced by the mixed-effects repeated measures
ANOVA procedure used to calculate the ICC, which pro-
vided evidence of an instrument effect (p=0.01). The Bland
and Altman plots for each pair-wise comparison showed
wide limits of agreement, except for the comparison be-
tween the SF-6D and SF-12 new algorithm, suggesting
these were the only two instruments that could be usedTable 1 Descriptive statistics at baseline and 12 month follow
Characteristic EQ-5D-3L
(n=395)
Age
mean (SD) 50.0 (11.6)
Gender
Female n (%) 293 (74.2%)
Male n (%) 102 (25.8%)
Suffered from depression in the past
Yes 353 (89.4%)
No 42 (10.6%)
Duration of current episode of depression
<2 years 95 (24.1%)
1-2 years 70 (17.7%)
>2 years 230 (58.2%)
BDI score at baseline
mean (SD) 31.3 (10.4)
BDI score at 12 months
mean (SD) 19.3 (13.6)
Health utility score at baseline*
mean (SD) 0.55 (0.31)
Health utility score at 12 months
mean (SD) 0.60 (0.35)
*n=390 for the SF-6D and SF-12 new algorithm for this variable.reasonably interchangeably (Figure 1). The plots also
showed that there was systematic variation between the
scores produced by the EQ-5D based instruments (EQ-
5D-3L and EQ-5D VAS) and the SF-6D and SF-12 new al-
gorithm. Less healthy individuals (those with a utility score
of <0.5) tended to have a higher score on the SF-6D and
SF-12 new algorithm compared with the EQ-5D based in-
struments, whereas healthier individuals tended to have
relatively high scores on the EQ-5D based instruments.
Sensitivity
Plots of the health utility score generated by each of the
different instruments against one another showed evi-
dence of ceiling effects in the EQ-5D-3L index scores
and floor effects in the SF-6D and SF-12 new algorithm
(Figure 2). When the EQ-5D-3L index shows “full health”
(a utility score of 1) the corresponding scores on the
SF-6D and SF-12 new algorithm were wide-ranging. The
plots also display a gap with no observations for the EQ-
5D-3L index between scores of 0.833 and 1; this represents
a range in which it is not possible to score using this in-
strument [32]. At the opposite end of the scale, however,
when the EQ-5D-3L index shows a score of 0 or below
(representing a state “equivalent to” or “worse than death”)
the scores on the SF-6D and SF-12 new algorithm were, at-up
EQ-5D VAS SF-6D SF-12 new algorithm
(n=394) (n=393) (n=393)
50.0 (11.6) 49.9 (11.6) 49.9 (11.6)
293 (74.4%) 291 (74.1%) 291 (74.1%)
101 (25.6%) 102 (25.9%) 102 (25.9%)
352 (89.3%) 351 (89.3%) 351 (89.3%)
42 (10.7%) 42 (10.7%) 42 (10.7%)
95 (24.1%) 94 (23.9%) 94 (23.9%)
70 (17.8%) 70 (17.8%) 70 (17.8%)
229 (58.1%) 229 (58.3%) 229 (58.3%)
31.3 (10.4) 31.2 (10.4) 31.2 (10.4)
19.3 (13.7) 19.2 (13.5) 19.2 (13.5)
0.51 (0.20) 0.56 (0.11) 0.57 (0.08)
0.59 (0.25) 0.62 (0.16) 0.62 (0.14)
Figure 1 Bland and Altman plots for agreement of health utility scores between instruments.
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the EQ-5D VAS showed a large amount of variation be-
tween scores.
The SF-12 new algorithm had the strongest negative
monotonic relationship with BDI score (Spearman’srho = −0.715). The other instruments also showed negative
monotonic relationships with BDI score but of smaller
magnitude: Spearman’s rho SF-6D = −0.689; EQ-5D-3L
index = −0.628; EQ-5D VAS = −0.529. The Tukey-Kramer
multiple comparison procedure provided evidence that
Figure 2 Scatter plots of health utility scores displaying ceiling and floor effects of instruments.
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ments did not differ between mild and moderate depres-
sion severity groups (Table 2). The SF-6D and SF-12 new
algorithm instruments produced utility scores that differed
between depression severity groups.Responsiveness to change
There was evidence of a difference in the ability of the
instruments to reflect a change in participants’ levels of
health. All instruments showed a reasonable ability to
discriminate between individuals who had “improved” in
Table 2 Ability of instruments to discriminate between levels of depression severity
Depression severity groups Utility score means by depression
severity group mean (SD)
Mean difference in
health utility score
Tukey-Kramer test statistic
(critical value = 3.649)^
EQ-5D-3L:
Not depressed vs Mild depression 0.797 (0.226) 0.670 (0.243) 0.128 4.242*
Mild depression vs Moderate depression 0.670 (0.243) 0.557 (0.295) 0.112 3.272
Moderate depression vs Severe depression 0.557 (0.295) 0.268 (0.352) 0.289 9.641*
EQ-5D VAS:
Not depressed vs Mild depression 0.713 (0.239) 0.586 (0.229) 0.127 5.247*
Mild depression vs Moderate depression 0.586 (0.229) 0.561 (0.209) 0.025 0.901
Moderate depression vs Severe depression 0.561 (0.209) 0.422 (0.211) 0.139 5.693*
SF-6D:
Not depressed vs Mild depression 0.725 (0.137) 0.624 (0.119) 0.102 7.843*
Mild depression vs Moderate depression 0.624 (0.119) 0.554 (0.096) 0.070 4.733*
Moderate depression vs Severe depression 0.554 (0.096) 0.482 (0.107) 0.072 5.505*
SF-12 new algorithm:
Not depressed vs Mild depression 0.732 (0.139) 0.617 (0.096) 0.116 9.796*
Mild depression vs Moderate depression 0.617 (0.096) 0.564 (0.073) 0.053 3.927*
Moderate depression vs Severe depression 0.564 (0.073) 0.505 (0.083) 0.059 4.947*
^The critical values for each comparison were the same at three decimal places.
* Indicates a test statistic greater than the critical value from the Studentized range distribution at the 5% alpha level.
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of the SF-6D and SF-12 new algorithm were very similar
and greater than those of the EQ-5D-3L and EQ-5D VAS.
The test for equality yielded strong evidence that the AUCs
were different from one another (p<0.0001) (Table 3). A
sensitivity analysis was carried out varying the point at
which the outcome was dichotomised. This had little im-
pact on the results (data not shown).Acceptability
The completion rates for each of the instruments were all
very high and extremely similar: EQ-5D-3L = 99.7%; EQ-
5D VAS = 99.5%; SF-6D = 99.2%; SF-12 new algorithm =
99.2%. The results of the Marascuilo Procedure provided
no evidence for any differences between the proportions
of respondents who provided enough information for theTable 3 Responsiveness of instruments to improvement
in depression
Utility instrument Area under the
ROC curve
95% confidence
interval
EQ-5D-3L 0.71 0.66 – 0.76
EQ-5D VAS 0.68 0.63 – 0.74
SF-6D 0.81 0.76 – 0.85
SF-12 new algorithm 0.80 0.76 – 0.85
p-value<0.0001 for test of equality of the AUCs.calculation of a health utility score for each of the four
different instruments (data not shown).Discussion
Findings
There was a substantial lack of agreement between
health utility measures in depressed subjects. The size of
the limits of agreement in the Bland and Altman plots
suggest that only the SF-6D and SF-12 new algorithm
instruments may be used relatively interchangeably. This
lack of agreement highlights the importance and rele-
vance of the second study objective (namely, assessing
the suitability of the instruments within a population of
depressed subjects) to those involved in health technol-
ogy assessments and policymakers.
The findings suggest that the SF-6D and SF-12 new al-
gorithm instruments had a greater sensitivity than the
EQ-5D instruments in depressed subjects. As expected,
all of the instruments showed a decreasing health utility
score with increasing BDI score (with the SF-12 new al-
gorithm having the strongest monotonic relationship),
but when respondents were classified into subgroups
according to severity of depression the EQ-5D based in-
struments could not adequately differentiate between
those with mild and moderate depression. The better
performance of the SF-6D and SF-12 new algorithm may
be because there are a greater number of possible re-
sponse categories, and hence health states, for the SF-12
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respectively) [34,35].
The results of plotting instrument scores against one
another also showed that the EQ-5D-3L was less sensi-
tive than the SF-6D and SF-12 new algorithm instru-
ments at the upper end of utility scores. There was a
wide range of scores on the SF-6D and SF-12 new algo-
rithm for those who scored one on the EQ-5D-3L index.
This is likely to be because it is not possible to produce
an index score for the EQ-5D-3L within the range 0.883
to 1, and again that there is a wider range of health
states defined for the SF-6D and SF-12 new algorithm
compared with the EQ-5D-3L [35,36]. At the other end
of the scale, however, the SF-6D and SF-12 new algo-
rithm instruments do not appear to be able to describe a
large range of very poor health states. The formulae used
to generate health utility scores from the SF-6D and SF-
12 new algorithm do not produce values close to or
below zero, and as such may be insensitive at the lower
end of the scoring continuum [13,23]. The consequences
of these ceiling and floor effects are that the EQ-5D-3L
may not adequately differentiate between different health
states at the top of the scale, whilst the SF-6D and SF-12
new algorithm instruments may not adequately differenti-
ate between health states at the lower end of the scale. In
terms of assessing changes in quality of life for specific
interventions, this means that the SF-6D and SF-12 new
algorithm instruments may underestimate changes in
quality of life for individuals in poorer health, but are
likely to be better than the EQ-5D-3L at detecting changes
in those at the higher end of the scale and therefore at
distinguishing between different severities of depression.
The SF-6D and SF-12 new algorithm instruments were
better able to discriminate between those who had
shown an improvement in depression severity and those
who had not in ROC analysis. This may again be attrib-
utable to the greater number of response categories for
the SF questionnaires. The time frame covered by the
questions may also have impacted on instrument re-
sponsiveness; the EQ-5D-3L asks questions about health
“today” whereas the acute version of the SF-12 question-
naire used in the CoBalT trial asks questions relating to
“the past week”, which may mean that the latter is more
sensitive to changes in health state compared with the
EQ-5D-3L [23].
Strengths and limitations
This investigation utilised a large sample size that was very
similar for all of the instruments compared. As a secondary
analysis of data the outcomes used in the investigation
would have been approached by the study participants
from a neutral point of view. However, no assessment of
test-retest reliability for the four instruments measuring
health utility was planned as part of trial.Responsiveness to change was examined using ROC
analysis, requiring the indicator of change to be a binary
variable, which may sacrifice information relating to the
size of change in health state [29]. On the other hand, a
sensitivity analysis was carried out varying the point at
which the outcome was dichotomised and this had no
impact on the conclusions drawn.
Acceptability was assessed in terms of the completion
rates of the four different instruments. Individuals com-
pleted the questionnaires in the presence of a researcher
who was able to clarify the meaning of a question if re-
quired. It is probably therefore not surprising that com-
pletion rates for all four instruments were very high. It
should therefore be noted that response rates might have
been different, and differed more between instruments,
had the instruments been completed without the pres-
ence of a research assistant – for example, as part of a
postal or online questionnaire.
The participants in this study had treatment resistant de-
pression and did not include those with a first or new epi-
sode of depression. However, it is widely recognised that
many patients do not respond to antidepressants [37] and
as such we believe our results to be generalisable.
Context of findings within previous work
The measurement of health related utility in patients with
depression has been very limited and the comparison of
different instruments within this patient population is al-
most non-existent. Lamers et al. [10] compared the utility
scores produced by the EQ-5D-3L and SF-6D and found
evidence of a difference in the mean utility scores of the in-
struments. However, the patients recruited had a wide
range of common mental health disorders, not just depres-
sion, and agreement was assessed by comparing the overall
mean scores of the instruments [10]. To the best of our
knowledge, only two previous studies have compared util-
ity scores generated by the EQ-5D-3L and SF-6D in a sam-
ple of depressed individuals in primary care (one from the
UK and one a sample from the Netherlands) [11,12]. The
previous UK study suggested that the EQ-5D-3L and SF-
6D performed similarly and that both were fairly insensi-
tive to differences in severity of depression. However, this
was a small study (n=114), presented primarily summary
statistics and again only assessed agreement by comparison
of the overall mean utility scores of the instruments [11].
The study from the Netherlands (using the Dutch EQ-5D
tariff) only assessed responsiveness to change, and found
little difference between the EQ-5D-3L and the SF-6D in a
sample of 267 participants [12]. The current study adds to
previous work by investigating not only the EQ-5D-3L and
SF-6D but also including the EQ-5D VAS and SF-12 new
algorithm, carrying out a more rigorous statistical analysis
of agreement, sensitivity, responsiveness and acceptability
and using a larger UK sample of depressed individuals.
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The lack of agreement between instruments measuring
health utility in those with depression means that cost-
effectiveness analyses may produce differing and poten-
tially conflicting conclusions as to whether or not an
intervention should be recommended for use in this
population. In order for there to be consistency between
the conclusions drawn from cost-effectiveness analyses a
single instrument should be recommended and utilised
in depression research – or, at the very least, there needs
to be greater knowledge than is presently available about
the implications of the choice of instrument. NICE cur-
rently recommends the EQ-5D-3L, but we found that
the EQ-5D-3L was insensitive in depressed patients. The
EQ-5D VAS is designed to elicit a participant’s own
valuation of their HRQoL, rather than generating a
population-based valuation. In the economic evaluation
of medical interventions it is public money that is being
considered and as such it seems appropriate to use
population valuations. For this reason the EQ-5D VAS is
unlikely to be used in cost-effectiveness analyses. There
was no difference in the acceptability of the instruments
in terms of completion rates, although, as outlined earl-
ier, these completion rates may be artificially inflated by
the presence of a research assistant who was able to clar-
ify queries during questionnaire completion. The SF-6D
and SF-12 new algorithm instruments outperformed the
EQ-5D-3L (and EQ-5D VAS) in terms of instrument
sensitivity and responsiveness to change. This suggests
that the SF-6D and SF-12 new algorithm instruments
may be more appropriate for use in depressed individ-
uals and could be used relatively interchangeably. How-
ever, as the SF-12 is frequently included as an outcome
measure in trials, the SF-12 new algorithm has the advan-
tage that it permits evaluation of health utility without the
need for an additional questionnaire, thus reducing patient
burden and potentially increasing follow-up rates.
NICE guidance currently states that the EQ-5D-3L
should be used for the estimation of QALYs in the as-
sessment of medical interventions. However, NICE per-
mits the use of alternative measures when there is
evidence that the EQ-5D-3L is not appropriate within a
specific patient group in terms of certain criteria such as
validity and responsiveness [4]. A new version of the
EQ-5D, the EQ-5D-5L, consisting of dimensions with
five levels rather than three has been developed in an at-
tempt to increase sensitivity and reduce the issue of ceil-
ing effects. The valuation exercise for this instrument is
still ongoing but once complete this instrument warrants
further investigation of the type presented here [38].
Nevertheless, this study suggests that a depressed popu-
lation may represent one such patient group where the
current form of the EQ-5D is not the most suitable in-
strument for the measurement of health utility and analternative method should be used. Further research is
needed to confirm and contextualise these findings in
populations of depressed patients who are not involved
in a clinical trial setting, and where account may be
taken of a range of data collection processes. In the
meantime, we would recommend the use of the SF-12
based instruments for the assessment of HRQoL in de-
pressed patients.
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